BeiGene
BGNE
#934
Rank
A$32.61 B
Marketcap
$293.13
Share price
-2.10%
Change (1 day)
-2.88%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : A$3.63 Billion

According to BeiGene 's latest financial reports the company's total liabilities are A$3.63 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31A$3.32 B13.5%
2022-12-31A$2.93 B-11.51%
2021-12-31A$3.31 B47.19%
2020-12-31A$2.25 B148.7%
2019-12-31A$0.90 B28.59%
2018-12-31A$0.70 B51.75%
2017-12-31A$0.46 B532.19%
2016-12-31A$73.39 M25.97%
2015-12-31A$58.26 M71.2%
2014-12-31A$34.03 M-39.92%
2013-12-31A$56.64 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
A$18.83 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.90 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA